High-dose naloxone formulations are not as essential as we thought.
Harm Reduction Journal · 2024-05-13 · Other / unclear
Abstract
Naloxone is an effective FDA-approved opioid antagonist for reversing opioid overdoses. Naloxone is available to the public and can be administered through intramuscular (IM), intravenous (IV), and intranasal spray (IN) routes. Our literature review investigates the adequacy of two doses of standard IM or IN naloxone in reversing fentanyl overdoses compared to newer high-dose naloxone formulations. Moreover, our initiative incorporates the experiences of people who use drugs, enabling a more practical and contextually-grounded analysis. The evidence indicates that the vast majority of fentanyl overdoses can be successfully reversed using two standard IM or IN dosages. Exceptions include cases of carfentanil overdose, which necessitates ≥ 3 doses for reversal. Multiple studies documented the risk of precipitated withdrawal using ≥ 2 doses of naloxone, notably including the possibility of recurring overdose symptoms after resuscitation, contingent upon the half-life of the specific opioid involved. We recommend distributing multiple doses of standard IM or IN naloxone to bystanders and educating individuals on the adequacy of two doses in reversing fentanyl overdoses. Individuals should continue administration until the recipient is revived, ensuring appropriate intervals between each dose along with rescue breaths, and calling emergency medical services if the individual is unresponsive after two doses. We do not recommend high-dose naloxone formulations as a substitute for four doses of IM or IN naloxone due to the higher cost, risk of precipitated withdrawal, and limited evidence compared to standard doses. Future research must take into consideration lived and living experience, scientific evidence, conflicts of interest, and the bodily autonomy of people who use drugs.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antidotes · Bystanders · Intranasal administration · Naloxone · Patient experience · Poisoning & substance use · Synthetic opioids
Related articles
- Trends and characteristics during 17 years of naloxone distribution and administration through an overdose prevention program in Pittsburgh, Pennsylvania. (PLoS One, 2025)
- The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews. (Am J Public Health, 2021)
- Naloxone dosing by non-medical first-responders at opioid overdoses: findings from a qualitative interview study. (Harm Reduct J, 2025)
- Examination of naloxone dosing patterns for opioid overdose by emergency medical services in Kentucky during increased fentanyl use from 2018 to 2021. (Drug Alcohol Depend, 2024)
- Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults. (Expert Opin Drug Metab Toxicol, 2022)
- Emergency Department-Administered Extended-Release Buprenorphine After Fentanyl Overdose Reversed by Emergency Medical Services With Naloxone. (J Emerg Med, 2026)